Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. - Archive ouverte HAL Access content directly
Journal Articles BMC Gastroenterology Year : 2011

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

(1) , (2) , (2) , (2) , (2) , (1) , (2) , (1) , (1) , (1)
1
2
Mona Munteanu
  • Function : Author
  • PersonId : 901279
Olivier Deckmyn
  • Function : Author
  • PersonId : 901280
Yen Ngo
  • Function : Author
  • PersonId : 901281
Fabienne Drane
  • Function : Author
  • PersonId : 901282
Jean Marie Castille
  • Function : Author
  • PersonId : 901284

Abstract

ABSTRACT: BACKGROUND: FibroTest (FT) is a validated biomarker of fibrosis. To assess the applicability rate and to reduce the risk of false positives/negatives (RFPN), security algorithms were developed. The aims were to estimate the prevalence of RFPN and of proven failures, and to identify factors associated with their occurrences. METHODS: Four populations were studied: 954 blood donors (P1), 7,494 healthy volunteers (P2), 345,695 consecutive worldwide sera (P3), including 24,872 sera analyzed in a tertiary care centre (GHPS) (P4). Analytical procedures of laboratories with RFPN>5% and charts of P4 patients in with RFPN were reviewed. RESULTS: The prevalence of RFPN was 0.52% (5/954; 95%CI 0.17-1.22) in P1, 0.51% (38/7494; 0.36-0.70) in P2, and 0.97% (3349/345695; 0.94-1.00) in P3. Three a priori high-risk populations were confirmed: 1.97% in P4, 1.77% in HIV centre and 2.61% in Sub-Saharan origin subjects. RFPN was mostly associated with low haptoglobin (0.46%), and high apolipoproteinA1 (0.21%). A traceability study of a P3 laboratory with RFPFN>5% permitted to correct analytical procedures. CONCLUSION: The mean applicability rate of Fibrotest was 99.03%. Independent factors associated with the high risk of false positives/negatives were HIV center, subSaharan origin, and a tertiary care reference centre, although the applicability rate remained above 97%.
Fichier principal
Vignette du fichier
1471-230X-11-39.pdf (234.98 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39-S1.DOCX (163.01 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39-S2.DOCX (77.2 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39-S3.DOCX (83.18 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39-S4.DOCX (111.24 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39-S5.DOCX (74.69 Ko) Télécharger le fichier
Vignette du fichier
1471-230X-11-39.xml (107.56 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other
Format : Other
Loading...

Dates and versions

inserm-00593975 , version 1 (18-05-2011)

Identifiers

Cite

Thierry Poynard, Mona Munteanu, Olivier Deckmyn, Yen Ngo, Fabienne Drane, et al.. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.. BMC Gastroenterology, 2011, 11 (1), pp.39. ⟨10.1186/1471-230X-11-39⟩. ⟨inserm-00593975⟩
213 View
259 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More